Kuros Biosciences AG Announces Launch of MagnetOs MIS Delivery System and Expands Globally

Schlieren, Switzerland, August 5, 2025 — Kuros Biosciences AG, a Swiss biotechnology company specializing in orthobiologics, has successfully launched its MagnetOs MIS Delivery System, marking a significant advancement in minimally invasive spine surgery. The company announced the completion of the first U.S. cases using this innovative system, which has received FDA 510(k) clearance in May 2025.

The MagnetOs MIS Delivery System is a sterile, prefilled, single-use delivery system designed specifically for minimally invasive spine procedures. It offers a streamlined approach for graft delivery, eliminating the need for preparation and thawing, thus allowing for immediate and efficient graft placement. Dr. Daniel Park, an orthopedic spine surgeon, performed the first case using the FDA-cleared system in Southfield, Michigan. He reported that the system facilitated smooth and precise graft placement in a challenging transforaminal lumbar interbody fusion (TLIF) case.

In addition to its U.S. operations, Kuros Biosciences continues to expand its global footprint. The company has recently achieved incremental clearance in Brazil, further extending its reach in the international market. This expansion aligns with Kuros Biosciences’ strategy to enhance access to its innovative biologic technologies worldwide.

Company Overview

Kuros Biosciences AG, headquartered in Schlieren, Switzerland, operates in the health care sector, focusing on biotechnology. The company is listed on the SIX Swiss Exchange and specializes in developing products for tissue repair and regeneration, particularly targeting orthobiologics. Kuros Biosciences offers solutions to fill bony defects in the human skeletal system and stimulate bone formation at injury sites. More information about their products and services can be found on their website, www.kuros.ch .

Financial Snapshot

As of August 3, 2025, Kuros Biosciences AG’s close price was CHF 27.68. The company’s market capitalization stands at CHF 1.15 billion. Over the past year, the stock has experienced a range between a 52-week high of CHF 32 on November 13, 2024, and a 52-week low of CHF 11.06 on August 7, 2024. The price-to-earnings ratio is currently -261.42, reflecting the company’s growth-focused strategy and investment in research and development.

Market Context

The Swiss Performance Index (SPI) has shown some volatility recently. On August 4, 2025, the SPI closed 0.23% lower at 16,486.77 points, with a trading range between 16,263.31 and 16,486.77 points. Since the beginning of 2025, the SPI has gained 6.24%, indicating a generally positive trend in the Swiss market despite short-term fluctuations.

Kuros Biosciences AG’s recent developments and strategic expansions are expected to contribute positively to its growth trajectory, aligning with the broader positive trends observed in the Swiss market.